Feline Mediastinal Lymphoma

Feline mediastinal lymphoma (FML) is a form of malignant lymphoma arising from lymphoid tissue within the cranial mediastinum, most commonly originating from the thymus or mediastinal lymph nodes. It represents one of the classical anatomic forms of feline lymphoma alongside alimentary, multicentric, and extranodal variants [5]. Historically, FML was strongly associated with young cats, the Siamese breed, and feline leukemia virus (FeLV) infection; however, the epidemiological profile has shifted markedly in the post-vaccination era [1][7]. It typically presents as a large mediastinal mass that causes progressive respiratory compromise due to pleural effusion and direct compression of thoracic structures [5].

Retroviral Association

Feline mediastinal lymphoma has a well-established historical association with FeLV infection. FeLV, a gammaretrovirus, integrates proviral DNA into the host genome and can activate oncogenes (particularly c-myc) or inactivate tumor suppressor genes, driving neoplastic transformation of T lymphocytes in the thymic tissue [5][7]. In pre-vaccination era studies, the majority of mediastinal lymphoma cases were FeLV-positive; however, since the widespread adoption of FeLV vaccination in many countries, the proportion of FeLV-positive cases among FML patients has declined significantly [1][7]. In areas with endemic FeLV infection, such as certain regions of Brazil, high rates of FeLV positivity among FML cats continue to be documented [2].

Immunophenotype

Feline mediastinal lymphoma is predominantly of T-cell origin, consistent with its thymic derivation. T-cell lymphomas arising from the thymus are typically high-grade and aggressive in behavior [1][5]. B-cell mediastinal lymphomas are reported but are considerably less common.

Signalment and Risk Factors

• ·Age: Historically described as a disease of young cats (often <5 years), though the post-vaccination era has seen cases occurring across a wider age range [1][7]
• ·Breed: The Siamese breed has historically been over-represented, though this association may be weakening in the post-vaccination era [1]
• ·FeLV status: Positive FeLV antigenemia remains a significant predisposing factor, particularly in unvaccinated populations and endemic regions [2][6]
• ·FIV co-infection: FIV (feline immunodeficiency virus) can cause immunosuppression that may secondarily predispose to lymphoid malignancies, though its direct oncogenic role is less clear than FeLV [7]

Pathological Mechanism

The neoplastic lymphoid cells proliferate and form a large expansile mass within the cranial mediastinum. This mass causes respiratory compromise through two main mechanisms: (1) direct compression of the trachea, bronchi, and lung lobes, and (2) accumulation of pleural effusion—often bilateral—due to lymphatic obstruction and increased vascular permeability. The pleural fluid in FML is typically a chylous or modified transudate, though exudates can also occur. As the disease progresses, invasion into adjacent structures (pericardium, great vessels, lung parenchyma) may occur [1][5].

Physical Examination and Initial Assessment

Diagnosis begins with recognition of the clinical syndrome: a young-to-middle-aged cat in respiratory distress with muffled thoracic sounds. Thoracocentesis performed both therapeutically and diagnostically often yields significant pleural fluid, temporarily relieving dyspnea and enabling further workup [5].

Imaging

• ·Thoracic radiography: Reveals a soft-tissue opacity in the cranial mediastinum, often with concurrent pleural effusion obscuring the cardiac silhouette. Tracheal displacement may be visible [1][5]
• ·Computed tomography (CT): Provides superior anatomical detail, delineating the mass margins, vascular involvement, and relationship to adjacent thoracic structures. CT can help characterize heart-base involvement and distinguish lymphoma from other mediastinal neoplasms [3]
• ·Thoracic ultrasonography: Useful for guiding fine-needle aspirate (FNA) or Tru-cut biopsy of the mediastinal mass, particularly when pleural effusion is present (fluid acts as an acoustic window) [1]

Cytology and Histopathology

• ·Fine-needle aspiration (FNA) cytology: The primary diagnostic tool. Ultrasound-guided FNA of the mediastinal mass typically yields a highly cellular sample of neoplastic lymphoid cells. Diagnosis of high-grade (large-cell) lymphoma can often be made cytologically [1][2]
• ·Pleural fluid cytology: Neoplastic lymphocytes are frequently found in the pleural effusion and can confirm the diagnosis when present
• ·Histopathology: Tissue biopsy (via ultrasound-guided Tru-cut, thoracoscopy, or surgery) provides definitive diagnosis and allows immunohistochemical (IHC) subtyping (T-cell vs. B-cell) when cytology is equivocal [1]
• ·Flow cytometry and PARR (PCR for antigen receptor rearrangements): Advanced molecular techniques that can confirm clonality and immunophenotype in ambiguous cases

Retroviral Testing

• ·All cats presenting with mediastinal lymphoma should be tested for FeLV antigen (ELISA or rapid immunochromatographic test) and FIV antibody, as retroviral status has prognostic implications [1][6]

Laboratory Findings

Routine hematology and serum biochemistry should be performed in all patients. Relevant findings may include:

Hypercalcemia, when present, should raise strong suspicion for lymphoma as the underlying cause and warrants urgent investigation [4].

Initial Stabilization

Before chemotherapy, respiratory stabilization is paramount. Therapeutic thoracocentesis to drain pleural effusion provides immediate relief and allows safer handling and further diagnostics [5]. Supplemental oxygen support should be provided to dyspneic cats.

Chemotherapy: The Cornerstone of Treatment

Chemotherapy is the primary treatment modality for FML, as the disease is systemic and surgical excision is not curative. Multiple protocols exist:

1. COP (Cyclophosphamide, Vincristine [Oncovin], Prednisolone) A commonly used first-line protocol, particularly in resource-limited settings. In a retrospective study of 92 cats with FML (predominantly FeLV-positive), COP achieved an overall response rate and was associated with measurable survival times [6]. The protocol is generally well-tolerated, though adverse effects including neutropenia, gastrointestinal signs, and sterile hemorrhagic cystitis (cyclophosphamide-related) are reported [6].

2. CHOP-based protocols (Cyclophosphamide, Doxorubicin [Hydroxydaunorubicin], Vincristine, Prednisolone) Multi-agent CHOP protocols are considered the standard of care for high-grade feline lymphoma at many referral centers. They generally offer superior response rates compared to COP for high-grade disease [5].

3. LOPH Protocol (Lomustine, Vincristine [Oncovin], Prednisolone, Hydroxydaunorubicin [Doxorubicin]) A novel lomustine-based protocol evaluated prospectively in cats with high-grade multicentric or mediastinal lymphoma in an FeLV-endemic region. The LOPH protocol demonstrated efficacy and an acceptable safety profile, with lomustine offering added CNS penetration as an alkylating agent [2].

Doxorubicin Considerations

Doxorubicin is a cornerstone of CHOP and LOPH protocols. Cats are more sensitive to doxorubicin-induced nephrotoxicity compared to dogs; renal function (BUN, CREA) should be monitored carefully before and during treatment [2][5]. Cardiotoxicity, while less common at standard feline doses, should also be considered.

L-Asparaginase

L-Asparaginase may be used as an induction agent or rescue agent, particularly for T-cell lymphomas, to achieve rapid cytoreduction and initial remission [5].

Radiation Therapy

Thoracic radiation has limited application in FML due to the proximity of radiosensitive structures (heart, lung, esophagus); however, it may be considered in select cases as a palliative measure.

Supportive Care

• ·Nutritional support: Assisted feeding or appetite stimulants for anorexic cats
• ·Anti-emetics (maropitant, ondansetron): To manage chemotherapy-induced nausea
• ·Antibiotics: For febrile neutropenia episodes
• ·Fluid therapy: To correct dehydration and support renal function, especially in hypercalcemic patients
• ·Corticosteroids alone (Prednisolone monotherapy): For owners who decline combination chemotherapy; prednisolone provides palliative benefit and may temporarily reduce tumor size, but is not curative and can induce resistance, compromising future combination therapy responses [5]

Feline mediastinal lymphoma is generally considered a high-grade malignancy with a guarded-to-poor prognosis, though meaningful survival times can be achieved with aggressive chemotherapy in a subset of patients.

Response to Chemotherapy

• ·In the post-vaccination era study by Fabrizio et al. (2014), cats with FML treated with combination chemotherapy achieved an overall response rate (complete + partial remission), with complete remission (CR) being a significant positive prognostic indicator for survival [1]
• ·Cats achieving complete remission had significantly longer survival times than those achieving only partial remission or no response [1]

Survival Times

• ·Median survival times reported in the literature vary depending on the protocol used, FeLV status, and whether complete remission is achieved
• ·In the study by Sunpongsri et al. (2022) evaluating COP in FeLV-positive FML cats, survival data highlighted the negative impact of FeLV positivity on outcomes, with FeLV-positive cats generally experiencing shorter survival times compared to FeLV-negative counterparts [6]
• ·The LOPH protocol study by Horta et al. (2021) reported outcomes for cats in an FeLV-endemic area, where the high burden of FeLV infection represented a significant prognostic challenge [2]
• ·Historical data generally report median survival times ranging from a few months to over one year depending on treatment intensity and remission status [1][5]

Prognostic Indicators

Based on the available literature, the following factors have been associated with prognosis [1][6]:

Overall Outlook

Without treatment, the prognosis is extremely poor, with survival measured in days to weeks due to progressive respiratory failure. With aggressive combination chemotherapy, meaningful quality-of-life remission periods are achievable in a proportion of cats, but long-term cure is rare [5][1].

FeLV Vaccination

The single most impactful preventive measure for feline mediastinal lymphoma is vaccination against FeLV. Widespread adoption of FeLV vaccination in countries such as the UK and the United States has been associated with a dramatic shift in the epidemiology of FML, with a decline in the proportion of young, FeLV-positive cases [1][7]. All cats—particularly those with outdoor access or multi-cat household exposure—should receive FeLV vaccination according to current guidelines.

Retroviral Testing and Management

• ·New cats entering a household should be tested for FeLV and FIV before introduction to resident cats
• ·FeLV-positive cats should be housed strictly indoors and separated from FeLV-negative cats to prevent horizontal transmission via saliva (mutual grooming, shared food/water bowls, bite wounds)
• ·Breeding of FeLV-positive cats should be strongly discouraged

Reducing Exposure Risks

• ·Limiting outdoor access reduces exposure to FeLV-infected stray cats
• ·In multi-cat environments (shelters, catteries), regular retroviral screening programs help identify and isolate infected individuals

Limitations of Prevention

Not all cases of FML are FeLV-associated; FeLV-negative cases do occur, potentially through alternative oncogenic mechanisms. For these cases, no specific preventive strategy has been identified in the current literature. General health maintenance, minimizing immunosuppressive conditions, and routine veterinary surveillance represent prudent but non-specific measures.